logo-loader
viewEXMceuticals

EXMceuticals lists new cannabis research license in Portugal as key step in new update

The Portuguese license is a key advance as it offers the chance to widen its reach in Europe

EXMceuticals -
The Portuguese license enables the company to import raw material fom Africa into Portugal

EXMceuticals Inc (CSE:EXM), a cannabis producer, has highlighted in its latest update a list of its recent achievements, which include winning a license for cannabis research in Portugal.  

At the close of October, EXMceuticals announced it had obtained a license for cannabis research and development from INFARMED, the Portuguese National Authority of Medicines and Health Products. The granting of the Portuguese license is a key advance as it offers the company the chance to widen its reach in Europe. Thanks to its receipt, EXMceuticals will have the chance to import, research and refine its cannabinoids and cannabis products in Europe. 

READ: EXMceuticals names chairman Jonathan Summers interim CEO

The Portuguese license enables the company to import raw material from Africa into Portugal and refine it inside an existing R&D facility and pilot refinery. 

EXMceuticals is now actively pushing forward with an initial cannabis importation, as well as the fit-out and licensing of the sizable industrial facility that has been leased to the south of Lisbon. Once licensed and constructed, this facility will require a substantial amount of raw and processed cannabis material to be available for refining.

“With its Portuguese license, EXMceuticals is making a leap forward with regards to its activities in the country and the European Union,” EXMceuticals said in a statement.

Last month, EXMceuticals took part in Portugal Medical Cannabis 2019, where studies on the medical benefits of cannabis were discussed by more than 400 cannabis industry executives.

Also on the list of company highlights was a recent interview with Investing News by chairman Jonathan Summers and chief operating officer Tanek Amin, which offered insights about how EXMceuticals has adopted a pharmaceutical-like approach to the cannabis market.

Other recent interviews included an October update on EXMceuticals’ work in Portugal by vice-president Julie Lemiuex at the MjMicro Conference in Beverly Hills as well as a presentation on milestones and financial projections by chairman Jonathan Summers at the German Equity Forum last November.

Quick facts: EXMceuticals

Price: 0.3 CAD

CSE:EXM
Market: CSE
Market Cap: $11.9 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of EXMceuticals named herein, including the promotion by the Company of EXMceuticals in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

EXMceuticals secures critical R&D license for its Portugal cannabis facilities

EXMceuticals Inc's (CSE:EXM) Jonathan Summers speaks to Proactive London's Andrew Scott following the news they've obtained a licence for cannabis research and development from the Portuguese government. The license was granted by INFARMED - the Portuguese National Authority of Medicines and...

on 30/10/19

2 min read